Recruiting

Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device

NCT07701161 · Neurogen Biomarking LLC

Recruiting

In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

About this study

This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.

Eligibility criteria

Inclusion Criteria: * AD Amyloid PET/CSF confirmed, healthy control, or amyloid-negative non-AD cognitive impairment Age 40-90 Able to complete Tasso and venipuncture collection Caregiver consent/assistance available if needed Exclusion Criteria: * Uncontrolled systemic conditions Recent surgery/hospitalization (3 months) Other dementia drug trial (2 months) Pregnancy Prior Donanemab or Lecanemab use

Study design

Enrollment target: 1000 participants

Age groups: adult, older_adult

Timeline

Starts: 2025-01-13

Estimated completion: 2026-08-01

Last updated: 2026-07-14

Primary outcomes

• Agreement between p-tau217 concentration in Tasso device capillary blood and venipuncture blood (Baseline)

Sponsor

Neurogen Biomarking LLC · industry

Contacts & investigators

ContactAnsam Eghzawi, MD · contact · ansam@neurogenbiomarking.com · +18109410076

ContactElisabeth Thijssen, PhD · contact · elisabeth@neurogenbiomarking.com · +16282788161

InvestigatorRany Aburashed · principal_investigator, Insight Health Systems

All locations (5)

Insigth Hospital and Medical Center ChicagoRecruiting

Chicago, Illinois, United States

Insight Hospital and Medical Center DearbornActive Not Recruiting

Dearborn, Michigan, United States

Insight Institute of Neurology and NeurosurgeryActive Not Recruiting

Flint, Michigan, United States

Memorial Healthcare HospitalActive Not Recruiting

Owosso, Michigan, United States

Wake Forest Baptist Medical CenterActive Not Recruiting

Winston-Salem, North Carolina, United States

View on ClinicalTrials.gov ↗Find similar trials